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Abstract
Background: Cystic fibrosis (CF) is the most common autosomal recessive life-shortening disease among
Caucasians. Studies exploring the prevalence of anxiety and depression in adult CF patients are few, show
inconsistent findings and rarely include comparisons with general populations. Prevalence and degree of
anxiety and depression were investigated in adult CF patients in Sweden, Belgium, Germany and the UK,
and compared to corresponding general population data.
Methods: Adult non-transplanted CF patients from the three largest CF-centres (out of four) in Sweden
(N = 129; Age range 18–70 years; 50 % women) completed the Hospital Anxiety and Depression Scale (HADS).
Studies using HADS in adult CF populations in the UK, Germany, and Belgium were included, as well as
HADS normative data from the corresponding general populations.
Results: No elevated risk for anxiety and depression was found among the CF patients. However, a Country x Group
interaction effect emerged; CF patients experienced a higher degree of anxiety than the general population in Sweden,
but not in the other countries, though this finding did not remain significant in a logistic regression analysis. In Sweden
the effect was limited to women. A Country x Group interaction effect was also found for Depression; CF patients
experienced lower degree of depression than the general population in Sweden, Germany and the UK, but not in
Belgium/Netherlands.
Conclusions: Contrary to earlier outcomes, the present results do not indicate any general elevated risk for anxiety and
depression among CF patients. Anxiety was slightly higher in the Swedish CF population, compared to the general
population; this finding was not seen in the other countries. Depression among CF patients was lower than or similar
to that in the general populations in the studied countries.
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Background
Cystic fibrosis (CF) is the most common autosomal re-
cessive, life-shortening disease among Caucasians [1].
The known genetic defect causes inappropriately thick
mucus and malfunctioning of epithelial organs such as
the lungs, pancreas and liver. CF is chronic and the
expected course of the disease is a progressive deterior-
ation of health resulting in decreasing lung function and
capacity. The primary cause of mortality and morbidity
in CF is progressive lung disease [2]. CF is still incurable;
the treatment offered is symptomatic and aims to post-
pone disease progression. The treatment is complex,
must occur daily and is extremely time consuming and
demanding for the patient [3]. However, centralized care
and advances in management and treatment of CF have
led to a substantial improvement in prognosis and
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survival during recent decades and, as a result, a grow-
ing adult patient population [2].
Chronic respiratory patients are generally at increased
risk for anxiety and depression [4–6]. Studies exploring
prevalence and levels of anxiety and depression in adult
CF patients are few, show inconsistent findings and rarely
include comparisons with general populations. According
to two reviews, anxiety [7] and depression [7, 8] appear to
be more common in CF patients than in the general
population, and a recent international multicentre study
[9] revealed high rates of depression and anxiety in CF pa-
tients. In contrast, a Belgian single-centre study [10] and a
recent large UK study [11] showed anxiety and depression
rates in CF patients similar to those in the respective gen-
eral populations. Furthermore, two smaller single-centre
studies conducted in Sweden [12] and the US [13] found
relatively healthy psychological functioning in CF patients.
Concerning prevalence estimates, two multicentre stud-
ies [11, 14] conducted in the UK among 1779 adults with
CF and among 670 German CF patients (aged 12–64
years) reported an anxiety prevalence of 34 and 20.6 %,
respectively, and depression prevalence of 13 and 9.6 %,
respectively. The multicentre study [9] mentioned above
found an anxiety prevalence of 32 % and depression
prevalence of 19 % among adult CF patients across coun-
tries. Two single-centre studies among 57 adult CF
patients in Belgium [10] and 121 in the UK [15] reported
elevated anxiety levels in 30 and 33 % of the patients,
respectively, and depression symptoms in 13 and 16 %,
respectively. An earlier review [7] presented prevalence
rates for depression ranging from 29 to 46 % and for anx-
iety from 0 to 31 %. Furthermore, a small single-centre
study [16] conducted in the US reported a depression
prevalence of 30 %.
In Sweden, only one study has looked at psychosocial
issues among CF patients [12]. An evaluation of anxiety
and depression rates in the Swedish adult CF population
is therefore needed. The aim of the present study, which
is in part the Swedish arm of The International Depres-
sion/anxiety Epidemiological Study (TIDES) [9], was to
compare data on prevalence and degree of anxiety and
depression among Swedish CF patients with correspond-
ing Swedish general population data. An additional aim
was to include previous anxiety and depression preva-
lence data from adult CF populations in other countries
and corresponding general populations in the compari-
sons. Due to previous conflicting outcomes and meth-
odological differences, between-population comparisons
were performed using similar measurements.
Method
Subjects
The three largest CF centres (out of four) in Sweden
recruited participants to the study; these were the adult
patients in the Swedish arm of TIDES. Patients of inter-
est were adults (≥18 years of age) with a confirmed CF
diagnosis. Transplanted patients were excluded because a
transplant changes the symptomatology, health status and
treatment regimen dramatically. After exclusion, 249 sub-
jects remained as potential participants. Participants were
129 voluntary CF patients: 50 % women; mean age: 30.4
(SD 11.73, range 18–70 years). Mean Forced Expiratory
Volume in one second (FEV1) per cent of predicted value
was 73.3 (SD 27.3, range 22–125).
Non-participant data were available only for the lar-
gest of the participating sites, where 27 % of potential
patients did not participate; 44 % women; mean age:
29.7 (range 19–65). Of those patients who did not
participate, 12 explicitly refused, 3 were living abroad
and the reasons the remaining 15 patients did not
participate were unknown.
Procedures
The procedures were in accordance with the TIDES [9]
protocol. The patients were invited to participate and in-
formed about the study via regular mail. The CF centre
staff then approached them by phone regarding partici-
pation. If they were interested in participating, an ap-
pointment with the CF team psychologist or social
worker was scheduled in connection with a routine out-
patient clinic visit. During this appointment and after
giving his/her written informed consent/assent, the pa-
tient completed the Hospital Anxiety and Depression
Scale (HADS) in the presence of a psychologist/social
worker who also collected demographic data. Comple-
tion of the questionnaire usually took <10 min. Patients
who had elevated HADS scores (+8) were followed up
by the CF team psychologist. Following data collection, a
medical check-up was performed. Data were collected
consecutively between March 2008 and February 2009.
Ethical approval was obtained from the Central Ethical
Review Board, Stockholm (reg. no. 2007/1266–31).
Measures
Anxiety and depression were measured using the Swedish
validated version [17] of HADS [18], a well-established
and well-validated screening tool with good psychometric
properties [19] developed for use in somatic populations.
HADS was developed based on the need for a short, easily
administered questionnaire that measures symptoms of
emotional distress but excludes symptoms deriving from a
physical disorder. The questionnaire consists of two sub-
scales – anxiety and depression – each containing 7 items
(range 0–3). Patient results are obtained by summing up
each subscale, yielding values from 0–21. Each subscale
has three ranges: 0–7 (non-cases), 8–10 (mild-moderate
anxiety/depression) and 11–21 (moderate-severe anxiety/
depression). The cut-off scores are defined based on the
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psychiatric ranges of anxiety and depression [18]. HADS
scores can be used in two ways: either by comparing an
individual’s score to normative values, or by using cut-off
scores indicating severity of distress levels [18, 20].
The previous studies used in the comparisons
The selected comparison countries were chosen because
data on them were available in the existing literature;
the articles were retrieved by searching PubMed, Med-
line and Google Scholar. Studies using HADS in adult
CF populations were of interest. The next step was to
find studies estimating HADS general population scores
for the same selected countries. Data on number of sub-
jects, age (range, mean and SD), sex distribution, HADS
Anxiety and Depression mean score and prevalence rate
were collected from the articles. In two of the studies
[14, 21], adolescent data (age <17) were included in the
original article; these data were excluded. The Swedish
general population data were taken from two different
studies [17, 21] to better match the total age range in
the present Swedish CF sample. Dutch general popula-
tion data [22] were used in the comparisons with the
Belgium CF sample because the authors of the original
article used them as a reference when they concluded
that the Belgium CF population scores were similar to
those of the general population.
Statistics
A dataset with the characteristics (N, M, SD, and fre-
quencies) presented in Tables 1 and 2 was simulated.
Two separate three-way ANOVAs were conducted with
Sex, Country, and Group (CF patient/General) as inde-
pendent variables, and with either HADS anxiety or
HADS depression as the dependent variable. Binary
logistic regression was used to analyse effects on the
odds of having an elevated score (≥8) on anxiety or
depression. Effects of age on HADS anxiety and de-
pression, as well as the effects of anxiety and depres-
sion on each other, were analysed using ordinary
linear regression. All analyses were conducted in IBM
SPSS Statistics 22.
Results
The three Swedish CF centres recruited a total of 52 %
of the potential participants – 72 %, 53 % and 21 % of
their clinic populations, respectively.
A dataset with the characteristics (N, M, SD, and fre-
quencies) presented in Table 1 was simulated. An
ANOVA with mean Anxiety as the dependent variable
and with Country, Group (CF patient/General popula-
tion), and Sex as factors revealed a significant main
effect of Sex, F(1, 9237) = 49.82, p < .001, η2 = .005, with
women (M = 5.66, SD = 3.95) experiencing higher levels
of anxiety compared with men (M = 4.94, SD = 3.59).
However, the effect of Sex was not moderated by Coun-
try or Group (CF patient/General population), and in
order to include the Belgian samples, which did not re-
port results separately for men and women, a simplified
two-way ANOVA, with Country and Group as factors,
was conducted (see Table 2 for descriptive values). This
analysis revealed a significant Country × Group inter-
action effect, F(3, 9618) = 2.96, p = .031, η2 = .001. Separ-
ate analyses for each country revealed that CF patients
experienced higher levels of anxiety than the general
population in Sweden, F(1, 927) = 4.56, p = .033, η2 = .005,
but not in the three other countries (all ps > .19). When
conducting a binary logistic regression separately for the
four countries, Group was not found to have a significant
effect on the odds of having an elevated score (≥ 8) on
Anxiety in any country (all ps > .17).
A significant Country × Group interaction effect was
found also for Depression, F(3, 9618) = 7.45, p < .001,
Table 1 Descriptive statistics for the present Swedish CF population as well as other CF and general populations
Age HADS_A HADS_D
Population N M Range M (SD) ≥ 8 (%) M (SD) ≥ 8 (%)
CF, Sweden (present) 129 30.4 18–70 5.5 (3.7) 27 3.0 (2.9) 9
General, Sweden [17] 624 44.0 30–59 4.6 (3.7) 20 4.0 (3.5) 15
General, Sweden [21]b 176 - 20–23 5.5 (4.0) 28.1a 3.1 (3.0) 9.5a
CF, UK [15] 121 30.0 18–70 6.1 (3.8) 33 3.6 (3.3) 16
CF, UK [11] 1779 - ≥ 18 6.1 (4.1) 34 3.4 (3.3) 13
General, UK [20] 1792 41.5 18–91 6.1 (3.8) 33 3.7 (3.1) 11
CF, Germany [14]b 343 - 21–50 4.9 (3.5) 22 3.2 (3.3) 12
General, Germany [23] 4410 50.3 ≥ 18 4.7 (3.5) 21 4.7 (3.9) 24
CF, Belgium [10] 57 26.7 - 5.6 (3.9) 30 3.5 (3.6) 13
General, Netherlands [22] 199 39.9 18–65 5.1 (3.6) 24.4a 3.4 (3.3) 11.9a
aNot presented in the article, predicted from the mean value
bExcluding the youngest age category
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η2 = .002. Sex had no main effect on Depression and
was not involved in any interaction effects with
Country or Group. Separate analyses for each country
revealed that CF patients experienced lower levels of
Depression than the general population in Sweden,
F(1, 927) = 5.95, p = .015, η2 = .006, the UK, F(1,
3686) = 13.25, p < .001, η2 = .004, and Germany, F(1,
4751) = 45.32, p < .001, η2 = .009, but not in Belgium,
F(1, 254) = 0.039, p = .844, η2 < .001. When conducting
a binary logistic regression separately for the four coun-
tries, being a CF patient had a significant negative effect
on the odds of having an elevated score (≥ 8) on Depres-
sion in Germany only, OR = 0.450, p < .001.
When restricting the analysis to the general popula-
tions, Country had a significant effect on anxiety, F(3,
7193) = 81.36, p < .001, η2 = .033, as well as on depres-
sion, F(3, 7193) = 38.57, p < .001, η2 = .016. According to
Tukey HSD Post Hoc Test, the general UK population
had a significantly higher level of anxiety than the three
other general populations (p < .001, p > .5 for the com-
parisons between Sweden, Germany, and Belgium), while
the general German population had a significantly
higher level of depression than the three other popula-
tions (p < .001, p > .4 for the other comparisons).
Sex/Age in the Swedish CF population
When limiting the analyses to the present Swedish CF
sample and to data simulating the Swedish general popu-
lation [17, 21], a Group (CF-patient/general population) ×
Sex interaction effect on Anxiety was found to be margin-
ally significant, F(1, 925) = 3.07, p = .080, η2 = .003. When
analysing the effect of Group separately for women and
men, CF patients were found to have a higher mean
among women, F(1, 512) = 16.17, p = .007, η2 = .014, but
not among men, F(1, 413) = 0.18, p = .676, η2 < .001
(Table 2). A similar analysis with Depression as the
dependent variable revealed an effect of Group (see
above), but this effect was not moderated by Sex, F(1,
925) = 0.10, p = .748, η2 < .001.
In Table 3, standardized regression coefficients (beta-
weights), when predicting HADS-A and HADS-D from
each other and age, are presented. Although not always
significant, age tended to have a negative association
with anxiety and a positive association with depression,
while anxiety and depression had a positive association
with each other.
Discussion
The present findings suggest no elevated risk for anxiety/
depression in CF patients compared to their respective
general populations, which is contrary to findings from
some previous studies [7–9]. However, the results indicate
that adult CF patients do have an elevated degree of anx-
iety compared to the general population in Sweden,
although not in the three other countries under study.
This outcome should be interpreted with caution, as the
effect did not remain when performing the logistic regres-
sion analysis, and the significant effect revealed in the
ANOVA was very weak. Furthermore, CF patients experi-
enced a lower degree of depression than that found for
the normal population in Sweden, the UK and Germany.
Table 2 Descriptive statistics, separate for men and women
Men Women
Population N HADS-A HADS-D N HADS-A HADS-D
CF, Sweden (present data) 65 4.5 (3.0) 3.0 (2.8) 64 6.5 (4.1) 3.0 (2.9)
General, Sweden [17] 267 4.3 (3.6) 4.3 (3.6) 357 4.8 (3.8) 3.8 (3.4)
General, Sweden [21]b 83a 4.6 (3.3) 2.8 (2.4) 93a 6.2 (4.5) 3.3 (3.4)
CF, UK [11] 929 5.7 (3.9) 3.4 (3.3) 850 6.6 (4.3) 3.4 (3.4)
General, UK [20] 810 5.7 (3.7) 3.6 (3.2) 978 6.8 (4.1) 4.0 (3.6)
CF, Germany [14]b 182 4.6 (3.5) 3.1 (3.3) 161 5.4 (3.5) 3.4 (3.4)
General, Germany [23] 1929 4.4 (3.3) 4.8 (4.0) 2481 5.0 (3.6) 4.7 (3.9)
aNot presented in the article, estimated
bExcluding the youngest age category
Table 3 Crude and adjusted effects of age, HADS anxiety, and
HADS depression
Lineara Logisticb
Predictor HADS-A HADS-D HADS-A HADS-D
Crude
Age -.015 .243* 0.795 1.405
HADS-A - .499** - 3.310**
HADS-D .499** - 2.127** -
Adjusted
Age -.144† .250** 0.573* 1.543
HADS-A - .502** - 3.417**
HADS-D .534** - 2.509** -
aThe values are standardized beta-weights
bThe values stand for the multiplicative change in the odds for anxiety and
depression (score ≥ 8) when the predictor increases by one
†p < .10; *p < .05; **p < .001
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However, this effect remained in the German sample only
when the logistic regression was conducted and might be
due to the higher mean age in the German general popu-
lation, given that depression seems to increase with age
[17, 23, 24].
In the Swedish sample, women with CF reported a
higher degree of anxiety than did women in the general
population, an effect not seen among the men. This is
contrary to recent findings among CF patients in the UK
[11, 15], where men with CF were more anxious than
healthy subjects, and women with CF reported a degree
of anxiety similar to normative scores. Furthermore,
consistent with previous studies in both CF populations
[9, 11, 14, 25] and general populations [17, 23, 24], age
tended to be positively associated with depression in the
Swedish CF sample. Contrary to other findings among
CF patients [9, 11, 14, 15], age tended to be negatively
associated with anxiety.
Because the present study did not investigate predic-
tors of anxiety and depression, it is difficult to explain
why CF patients showed an elevated degree of anxiety in
Sweden but not in the other three countries. From an
international perspective, Swedish CF patients have been
found to have good pulmonary function, health status
and a high survival age [26–28]. The FEV1 in the present
CF sample was also relatively high and, thus, the ele-
vated degree of anxiety found should not be due to poor
health status, but could instead be related to treatment
regimen issues. It is well known that CF treatment is de-
manding [3, 29]. Since the 1980s, the Swedish treatment
regimen, on top of the standard treatment, has included
frequent physical training as an essential part, and daily
airway clearance therapy is based on physical exercise
and chest physiotherapy [26]. Furthermore, monthly
medical check-ups and home intravenous antibiotic
treatment have been standard since the 1980s [30, 31]. It
is possible that this expanded treatment burden/respon-
sibility contributes to an elevated degree of anxiety in
the patient group. However, this does not explain why
elevated anxiety scores were found only among female
CF patients in Sweden.
There are some limitations regarding the low levels of
depression symptoms found in the present CF popula-
tions. First, it is possible that the HADS underestimates
depression. In a recent study among CF patients com-
paring HADS with another screening tool (Patient
Health Questionnaire for depression; PHQ-9), discrep-
ancies were found in depression estimates [32]. Further-
more, another recent study [9] revealed that several
limitations were found in more recent evaluations of
HADS. Second, as already mentioned, some previous
studies [17, 23, 24] have indicated that depression in-
creases with age. Another possible explanation for the
low depression scores in the present CF samples, as
compared to their corresponding general populations, is
the higher mean age in some of the present general pop-
ulations. The depression rates should therefore be inter-
preted with caution.
This is the first study to systematically investigate the
prevalence and degree of anxiety and depression in a
Swedish adult CF population. However, at one of the
participating sites, both the response rate and depression
mean scores were very low, which affected the represen-
tativeness negatively. Because refusal data are only avail-
able for one centre, selection bias cannot be excluded.
The Swedish general population data were taken from
two studies with different age ranges so as to better
match the total age range in the Swedish CF sample, and
our comparisons may therefore have been affected by
methodological issues and potential changes in anxiety
and depression prevalence over time. Another limitation
is the present use of existing HADS normative data in-
stead of matched control subjects, which would have
been a preferable approach. The characteristics of the
present normative samples differ from those of the cor-
responding CF populations. For example, the mean ages
of the different samples vary and are higher than in
some of the present CF populations. The samples also
vary in size, and some of the general population data are
old compared to the corresponding CF population data.
Because the results do not indicate elevated risks for
anxiety and depression among CF patients, it should also
be noted that the countries under study are wealthy and
provide some kind of public/universal health insurance
system, possibly eliminating stressors that may have an
impact on psychological wellbeing. Furthermore, pre-
vious studies [33–35] have shown great differences
across European countries concerning both availability
of specialist CF care, and demography, mortality, and
health status in the CF populations. Generalizing
these results to other CF populations should therefore
be done with caution.
From a clinical perspective, anxiety and depression
among CF patients should be seen as risk factors that
could have a negative impact on adherence to treatment
[36–38] and quality of life. Psychological competence
should therefore be integrated into CF care. In Sweden,
psychologists have been part of CF care for more than
two decades, which may have contributed to the low
prevalence of anxiety and depression found in the
present study. However, more work has to be done
because our results do indicate an elevated degree of
anxiety in the Swedish CF population.
Conclusions
On the whole, the present results do not indicate any
elevated risks for anxiety and depression within the
studied CF populations, and depression mean scores
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among CF patients were lower than or similar to those
of the general population, a finding that requires further
research using measurements that are more sensitive to
depression symptoms. However, the degree of anxiety
was higher among the Swedish CF patients compared to
the general population, although this difference was not
seen in the UK, Germany and Belgium. Explaining the
low prevalence of anxiety and depression found in the
present countries requires further research. Such re-
search may help in developing treatment programs for
CF populations in which high prevalence of anxiety and
depression is a serious problem.
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